Taking stock of the drug industry, from the lab to the medicine chestJune 23, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Drew Angerer/Getty Images STAT+ | GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac The lawsuit argued GSK knew the active ingredient in Zantac, which is called ranitidine, degraded and transformed into a potential carcinogen By Ed Silverman Biden directs HHS to boost contraception access, a year after Dobbs decision A year after the Dobbs decision, President Biden Friday directed federal health officials to boost contraception access. By Sarah Owermohle 'We fail people': New data on disparities in Medicaid access to opioid addiction treatment Medicaid patients are already at disproportionate risk of opioid overdoses, almost four times higher than patients on commercial insurance. By Simar S. Bajaj Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT+ | At a defunct power station, the U.K. and Moderna celebrate a partnership meant to be an engine for science Under the partnership, the company will invest in mRNA research programs and is constructing the Moderna Innovation and Technology Center. By Andrew Joseph More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments